Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 4
1966 3
1969 1
1970 2
1971 4
1972 3
1973 2
1974 4
1975 11
1976 14
1977 20
1978 9
1979 18
1980 17
1981 13
1982 22
1983 21
1984 37
1985 27
1986 36
1987 33
1988 21
1989 24
1990 29
1991 54
1992 60
1993 73
1994 109
1995 81
1996 72
1997 78
1998 57
1999 82
2000 80
2001 81
2002 85
2003 74
2004 96
2005 55
2006 68
2007 66
2008 70
2009 95
2010 99
2011 119
2012 120
2013 101
2014 113
2015 123
2016 122
2017 143
2018 147
2019 169
2020 157
2021 144
2022 147
2023 113
2024 88
2025 116
2026 73

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,563 results

Results by year

Filters applied: . Clear all
Page 1
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia.
Brown JR, Seymour JF, Jurczak W, Aw A, Wach M, Illes A, Tedeschi A, Owen C, Skarbnik A, Lysak D, Eom KS, Šimkovič M, Pavlovsky MA, Kater AP, Eichhorst B, Miller K, Munugalavadla V, Yu T, de Borja M, Ghia P; AMPLIFY investigators; AMPLIFY Investigators. Brown JR, et al. N Engl J Med. 2025 Feb 20;392(8):748-762. doi: 10.1056/NEJMoa2409804. Epub 2025 Feb 5. N Engl J Med. 2025. PMID: 39976417 Clinical Trial.
Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.
Munir T, Girvan S, Cairns DA, Bloor A, Allsup D, Varghese AM, Gohil S, Paneesha S, Pettitt A, Eyre T, Fox CP, Forconi F, Kennedy B, Balotis C, Pemberton N, Sheehy O, Gribben J, Elmusharaf N, Gatto S, Preston G, Schuh A, Walewska R, Duley L, Webster N, Dalal S, Rawstron A, Howard D, Hockaday A, Jackson S, Greatorex N, Bell S, Stones D, Brown JM, Patten PEM, Hillmen P; UK CLL Trials Group. Munir T, et al. N Engl J Med. 2025 Sep 25;393(12):1177-1190. doi: 10.1056/NEJMoa2504341. Epub 2025 Jun 15. N Engl J Med. 2025. PMID: 40521799 Free article. Clinical Trial.
Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome.
Jeppsson A, James S, Moller CH, Malm CJ, Dalén M, Vanky F, Modrau IS, Andersen K, Anttila V, Atroshchenko GV, Barbu M, Dreifaldt M, El-Akkawi AI, Friberg Ö, Gudbjartsson T, Gunn J, Haaverstad R, Halonen J, Hansson EC, Holm J, Husso A, Juvonen T, Jakobsen Ø, Jideus L, Johannesson E, Jonsson Holmdahl A, Jonsson K, Kolseth SM, Krasniqi L, Mäkelä T, Mennander A, Mohagen Krogstad LE, Rafiq S, Raivio P, Riber L, Tahir A, Thorsen C, Tønnessen T, Wahba A, Zindovic I, Pivodic A, Nielsen SJ, Erlinge D, Alfredsson J, Sartipy U; TACSI Trial Group.; TACSI Trial Group. Jeppsson A, et al. N Engl J Med. 2025 Dec 11;393(23):2313-2323. doi: 10.1056/NEJMoa2508026. Epub 2025 Sep 1. N Engl J Med. 2025. PMID: 40888737 Clinical Trial.
Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes.
Guimarães PO, Franken M, Tavares CAM, Antunes MO, Silveira FS, Andrade PB, Bergo RR, Joaquim RM, Tinoco de Paula JE, Nascimento BR, Pitta FG, Arruda JA, Serpa RG, Ohe LN, Mangione FM, Furtado RHM, Ferreira E, Sampaio FBA, T do Nascimento C, Genelhu LOO, Bezerra CG, Sarmento-Leite R, Maia LN, Oliveira FRA, Wainstein MV, Dall'Orto FTC, Monfardini F, Assis SRL, Nicolau JC, Sposito AC, Lopes RD, Onuma Y, Valgimigli M, Angiolillo DJ, Serruys PWJC, Berwanger O, Bacal F, Lemos PA; NEO-MINDSET Trial Investigators. Guimarães PO, et al. N Engl J Med. 2025 Nov 27;393(21):2095-2106. doi: 10.1056/NEJMoa2507980. Epub 2025 Aug 31. N Engl J Med. 2025. PMID: 40888723 Clinical Trial.
Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA.
Wang Y, Meng X, Wang A, Xie X, Pan Y, Johnston SC, Li H, Bath PM, Dong Q, Xu A, Jing J, Lin J, Niu S, Wang Y, Zhao X, Li Z, Jiang Y, Li W, Liu L, Xu J, Chang L, Wang L, Zhuang X, Zhao J, Feng Y, Man H, Li G, Wang B; CHANCE-2 Investigators. Wang Y, et al. N Engl J Med. 2021 Dec 30;385(27):2520-2530. doi: 10.1056/NEJMoa2111749. Epub 2021 Oct 28. N Engl J Med. 2021. PMID: 34708996 Clinical Trial.
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.
Munir T, Cairns DA, Bloor A, Allsup D, Cwynarski K, Pettitt A, Paneesha S, Fox CP, Eyre TA, Forconi F, Elmusharaf N, Kennedy B, Gribben J, Pemberton N, Sheehy O, Preston G, Schuh A, Walewska R, Duley L, Howard D, Hockaday A, Jackson S, Greatorex N, Girvan S, Bell S, Brown JM, Webster N, Dalal S, de Tute R, Rawstron A, Patten PEM, Hillmen P; National Cancer Research Institute Chronic Lymphocytic Leukemia Subgroup. Munir T, et al. N Engl J Med. 2024 Jan 25;390(4):326-337. doi: 10.1056/NEJMoa2310063. Epub 2023 Dec 10. N Engl J Med. 2024. PMID: 38078508 Clinical Trial.
Ticagrelor-Associated Urticaria.
Zaidi SMJ, Ishaq U, Malik J, Nadir M, Almas T. Zaidi SMJ, et al. Am J Ther. 2023 Nov-Dec 01;30(6):e580-e583. doi: 10.1097/MJT.0000000000001523. Epub 2022 May 31. Am J Ther. 2023. PMID: 35639409 No abstract available.
Prasugrel-related hepatotoxicity.
Dogan Z, Yurtdas M, Bektasoglu G. Dogan Z, et al. J Pak Med Assoc. 2022 Nov;72(11):2295-2297. doi: 10.47391/JPMA.3179. J Pak Med Assoc. 2022. PMID: 37013306 Free article.
Safety Assessment of Adenosine as Used in Cosmetics.
Cherian P, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Fiume M, Heldreth B. Cherian P, et al. Int J Toxicol. 2024 Feb;43(1_suppl):50S-63S. doi: 10.1177/10915818231221790. Epub 2023 Dec 25. Int J Toxicol. 2024. PMID: 38146080
3,563 results